Before you read on, please be aware that the analysis below is my opinion only and may include flawed assumptions and inaccuracy of logic; therefore, caveat emptor applies here. Furthermore, all emphasis (color-coded, boldness, and underlined) on the excerpts are my own.
The bull bumped its head against the resistance this week but recovered to face the resistance again by the end of the week. Next week will be telling. Either the market goes up or corrects from here. It is still too soon to say until we see February.
I didn’t do much this week but to witness $CGC sped ahead without me. So much for the double-top scenario. I will continue to look for an opportunity to jump back in.
I’m beginning to get a feeling that $AEMD and $IBIO are approaching a pivotal point where everything is going to change for the better. My 2 cents is that we may hear breaking news of vital importance that may warrant a violent jump in price movement. If someone wants to buy Aethlon for its hemopurifier medical device, it will need to consider iBio for its ability to supply the hemopurifier’s bio-materials at an economical cost. Logically speaking, you really can’t use the hemopurifier without the bio-materials supplied by iBio. To do otherwise will incur a significant increase in the production cost of the bio-materials. Mammalian cells system will be cost prohibited if the plant-based tech is not utilized.
Over the week, contributors at Stocktwits provided some interesting information. From the Aethlon’s front, @pitkineagle from Stocktwtis reminded us of the following from recent Form 8K filing regarding the hiring of an interim CEO Dr. Rodell:
Basically, it seems to me that Dr. Rodell might be hired to handle the strategic transaction related to the recent Aethlon’s hemopurifier Breakthrough Device Designation awarded by the FDA for metastatic cancer treatment.
Another nugget of information is that iBio is hiring more people. Take a look at the link below that takes you to the positions iBio is looking to fill.
One of the position is Accounts Payable/Receivable Clerk. This new position means they have enough new businesses to justify hiring a new person to handle billing such as invoicing to keep up with the pace.
In summary, despite uncertainty, there is a lot of signs on the wall that point to positive developments; so, I’m excited about these two companies.
$LRAD is slowly bouncing off the weekly 79 & 89 MA supports. As seen on the weekly chart above, it looks like it is ready to bounce higher. I’m very bullish on LRAD’s technology, so I don’t have a problem waiting on this one.
$SOLO – I am a believer in the single-seater EV; therefore, I expect the Solo to sell very well as soon as new batches of the Solo arrived from China. While we are waiting for the second quarter and onward to see a ramp up on the production run, I will be looking to accumulate more $SOLO with profits I expect to make from other positions.
Due to downdraft on $IBIO, $AEMD, and $SOLOW, my port gave back gain for the week.
Current positions (in alphabet order):
Stocks = AEMD IBIO LRAD SOLO
Call options and warrant = CARA TRXC SOLOW
Plus cash (up 0.4% YTD)
My 2 cents
From my camera: